Back to top

Image: Bigstock

AngioDynamics Inc.

Read MoreHide Full Article

Over the last three months, AngioDynamics has outperformed the broader industry in terms of price.  Meanwhile, the company reported a mixed third quarter of fiscal 2017, wherein adjusted earnings surpassed the Zacks Consensus Estimate while revenues missed the same. The company has also provided positive earnings guidance for fiscal 2017. Notably, the major growth drivers for the company are the Perpheral Vascular, the NanoKnife and BioFlo Midline product lines. Meanwhile, the discontinuity of the Celerity tip location program under its vascular segment might dent operational efficiency over the long haul. A sluggish capital spending environment is adversely affecting AngioDynamics’ top-line growth. AngioDynamics is exposed to a stringent regulatory environment. Regulatory setbacks might dampen approvals for pipeline products, which will in turn hurt overall growth.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AngioDynamics, Inc. (ANGO) - free report >>

Published in